Deutsche Bank has raised its view on Uniphar Plc, moving the stock from a "hold" to a "buy" rating and assigning a new price target of €5 per share. The upgrade reflects the brokerage's view that the market is still tying Uniphar's valuation too closely to its defensive distribution business rather than the faster-growing, higher-margin units.
Valuation and re-rating thesis
In its analysis Deutsche Bank notes a disconnect between the multiple at which Uniphar currently trades and what it believes is justified as the group's revenue mix shifts. The firm reports that a sum-of-the-parts assessment places the stock at roughly 9x EV/EBITDA today, while a justified multiple for the business mix is closer to 11.5x. Deutsche Bank says this gap could underpin a re-rating of the shares and believes the shift in mix could support upside toward about €6 per share.
Broker rationale on business mix
Analyst Kane Slutzkin argued that the market "anchors valuation to its defensive, lower-growth, lower-margin Supply Chain & Retail business, overlooking the growing contribution from its higher-growth, higher-margin Medtech & Pharma divisions." That judgment is central to Deutsche Bank's decision to lift the recommendation.
The brokerage frames Uniphar as a company combining a stable distribution platform with accelerating operations in medical technology and pharmaceutical services. It highlights Supply Chain & Retail as a source of resilient cash flow, noting the unit's leadership in Irish pharmaceutical distribution and the potential for further efficiency gains from a new distribution centre.
Separately, Deutsche Bank emphasizes the Medtech segment for its exposure to specialist medical technologies across European healthcare systems, pointing out that the division has "doubled EBITDA since 2018" and that additional upside is expected as that trend continues.
Key takeaways
- Deutsche Bank upgraded Uniphar to buy and set a €5 price target, citing a valuation gap tied to changing business mix.
- The firm's sum-of-the-parts work finds the stock trading near 9x EV/EBITDA versus a justified multiple of about 11.5x, implying scope for re-rating.
- The Supply Chain & Retail arm provides defensive cash flow and market leadership in Irish distribution, while Medtech and Pharma are higher-growth, higher-margin contributors.
Risks and uncertainties
- Valuation depends on a continued shift toward higher-margin Medtech and Pharma contributions; if the mix does not change as projected, the re-rating thesis may not materialize - this directly impacts healthcare and equity markets.
- Operational improvements, such as efficiencies from the new distribution centre, are cited as potential upside; delays or underperformance in realizing those efficiencies would introduce downside risk - this affects the logistics and distribution segment of the market.
- Expectation of further Medtech EBITDA growth underpins part of the valuation case; if EBITDA does not continue to expand, the stock's justified multiple could be lower than Deutsche Bank anticipates - this influences investors focused on healthcare and growth-oriented equities.